All-Trans Retinoic Acid for the Treatment of Hemophagocytic Lymphohistiocytosis
Trial statusNot yet recruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18-65
SponsorBeijing Anzhen Hospital
About this trial
This study is designed to evaluate the safety and preliminary efficacy of all-trans retinoic acid (ATRA) as an initial treatment for patients with active hemophagocytic lymphohistiocytosis (HLH). HLH is a severe hyperinflammatory syndrome caused by excessive activation of immune cells and uncontrolled cytokine release. Current treatment often requires intensive immunosuppressive or cytotoxic therapy, which may be associated with significant toxicity.
ATRA is an orally available agent that has been widely used in other hematologic diseases and has immunomodulatory effects. Preclinical studies suggest that ATRA may help control HLH-related inflammation and improve immune dysregulation. In this study, patients with newly diagnosed or treatment-naïve active HLH will receive ATRA-based initial therapy. The study will assess clinical response, changes in HLH-related inflammatory markers, organ function, viral or disease-related parameters when applicable, and treatment-related adverse events.
The goal of this study is to determine whether ATRA can provide a safe and feasible initial therapeutic approach for active HLH and support further clinical development of ATRA-based treatment strategies in this disease.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
1. Age ≥18 years.
Patients diagnosed with active hemophagocytic lymphohistiocytosis according to HLH-2004 diagnostic criteria or the investigator's clinical assessment.
Newly diagnosed or treatment-naïve active HLH requiring initial HLH-directed therapy.
Presence of active disease manifestations, including at least one of the following: persistent fever, cytopenia, hyperferritinemia, splenomegaly, hypofibrinogenemia and/or hypertriglyceridemia, elevated soluble CD25, hemophagocytosis, reduced or absent NK-cell activity, or other HLH-related organ involvement.
Disqualifiers
Prior systemic HLH-directed therapy for the current HLH episode, including etoposide-based therapy, ruxolitinib, emapalumab, alemtuzumab, PD-1 blockade, or other investigational HLH-directed treatment. Short-term corticosteroids, supportive care, anti-infective therapy, or emergency treatment before enrollment may be allowed at the investigator's discretion.
Known hypersensitivity to all-trans retinoic acid, tretinoin, retinoids, or any component of the study drug.
Pregnant or breastfeeding women.
Patients with acute promyelocytic leukemia or other diseases for which ATRA is being used as standard leukemia-directed therapy.
Trial design
Design model
Single group
Treatments tested in this trial
ATRA
DrugAll-trans retinoic acid (ATRA) will be administered orally as frontline treatment for patients with active hemophagocytic lymphohistiocytosis (HLH). ATRA will be given at a dose of 45 mg/m²/day in two divided doses, according to the study protocol. Dose rounding, dose reduction, temporary interruption, or discontinuation will be allowed based on toxicity, organ function, and investigator assessment. Standard supportive care, anti-infective treatment, transfusion support, organ function support, and treatment of underlying triggers or diseases are permitted. Additional HLH-directed therapy or rescue treatment may be introduced at the investigator's discretion for patients with inadequate response, disease progression, or life-threatening clinical deterioration.
Treatment groups
30 Participants
are divided into 1 treatment groupGroup A: TreatmentExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
ATRA Efficacy for HLH
Overall response rate will be assessed at Week 4 and week 8 after initiation of ATRA treatment. Overall response is defined as achievement of complete response, partial response, or HLH improvement. Complete response is defined as normalization of HLH-related clinical and laboratory abnormalities, including resolution of fever and splenomegaly, recovery of cytopenias, improvement of coagulation abnormalities, reduction of hyperferritinemia, absence of active central nervous system manifestations, and no sustained worsening of soluble CD25 levels. Partial response is defined as normalization of at least three HLH-related abnormalities. HLH improvement is defined as at least 50% improvement from baseline in at least three HLH-related abnormalities. HLH-related abnormalities to be assessed include fever, splenomegaly, central nervous system symptoms when present, complete blood count, fibrinogen and/or D-dimer, serum ferritin, and soluble CD25.
Time frame
From enrollment to the end of treatment at 8 weeks2
Adverse effects of ATRA
Safety will be assessed by the incidence, severity, seriousness, and relationship to study treatment of treatment-emergent adverse events. An adverse event is defined as any unfavorable and unintended sign, symptom, disease, or abnormal laboratory finding that occurs after initiation of ATRA treatment, whether or not considered related to ATRA. Adverse events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events. Serious adverse events, grade 3 or higher adverse events, adverse events leading to dose interruption, dose reduction, treatment discontinuation, rescue HLH-directed therapy, hospitalization, or death will be recorded and summarized.
Time frame
From enrollment to the end of treatment at 8 weeksSecondary outcomes
1
Survival of HLH patients
Overall survival will be assessed from the date of initiation of ATRA treatment to the date of death from any cause. Patients who are alive at the time of analysis will be censored at the date of last follow-up. Survival status will be recorded during the study treatment period and follow-up period.
Time frame
From initiation of ATRA treatment up to 6 monthsLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: